RT Journal Article
T1 Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)
A1 Otero, Remedios
A1 Solier-López, Aurora
A1 Sánchez-López, Verónica
A1 Oto, Julia
A1 Arellano, Elena
A1 Marín, Samira
A1 Jara-Palomares, Luis
A1 Elías, Teresa
A1 Asencio, María Isabel
A1 Blasco-Esquivias, Isabel
A1 Rodríguez de la Borbolla, María
A1 Sánchez-Díaz, José María
A1 Real-Domínguez, María Macarena
A1 García-Cabrera, Emilio
A1 Rodríguez-Martorell, Francisco Javier
A1 Medina, Pilar
K1 Tromboembolismo
AB The most appropriate duration of anticoagulant treatment for cancer-associated venous thromboembolism (CAT) remains unclear. We have conducted a prospective multicenter study in CAT patients with more than 6 months of anticoagulant treatment to predict the risk of venous thromboembolism (VTE) recurrence after anticoagulation discontinuation. Blood samples were obtained when patients stopped the anticoagulation, at 21 days and at 90 days. In each sample we assessed different coagulation-related biomarkers: D-dimer (DD), high-sensitivity C-reactive protein (hs-CRP), P-selectin (PS), phospholipids, soluble tissue factor, factor VIII and the thrombin generation test. It was evaluated 325 CAT patients and 166 patients were included in the study, mean age 64 ± 17 years. VTE recurrence until 6 months after stopping anticoagulation treatment was 9.87% [95% confidence interval (CI): 6–15]. The biomarkers sub-distribution hazard ratios were 6.32 for ratio DD basal/DD 21 days > 2 (95% CI: 1.82–21.90), 6.36 for hs-CRP > 4.5 (95% CI: 1.73–23.40) and 5.58 for PS > 40 (95% CI: 1.46–21.30) after 21 days of stopping anticoagulation. This is the first study that has identified the DD ratio, hs-CRP and PS as potential biomarkers of VTE recurrence in cancer patients after the discontinuation of anticoagulation treatment. A risk-adapted strategy may allow the identification of the optimal time to withdraw the anticoagulation in each CAT patientm
PB IOAP-MPDI
YR 2022
FD 2022-06-02
LK https://hdl.handle.net/10630/24503
UL https://hdl.handle.net/10630/24503
LA eng
NO Otero R, Solier-López A, Sánchez-López V, Oto J, Arellano E, Marín S, Jara-Palomares L, Elías T, Asencio MI, Blasco-Esquivias I, Rodríguez de la Borbolla M, Sánchez-Díaz JM, Real-Domínguez M, García-Cabrera E, Rodríguez-Martorell FJ, Medina P. Biomarkers of Venous Thromboembolism Recurrence after Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study). Cancers. 2022; 14(11):2771. https://doi.org/10.3390/cancers14112771
NO This research was funded by Instituto de Salud Carlos III, grant number (PI15/01085; PI18/01640,PI20/00075), Sociedad Española de Trombosis y Hemostasia; Fundación Respira, grant number (140/2013),Fundación Neumosur, grant number (5/2013) and the LEO Pharma Research Foundation. Partial funding for open access charge: Universidad de Málaga.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 23 ene 2026